

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/524,963	First Named Inventor: David William Tonge
Filing Date: 02/18/2005	Attorney Docket No.: 100815-1P US
Examiner: Leslie A. Royds	Group Art Unit: 1614
Customer No.: 44992	Confirmation No.: 3567
Title: N-(-3-METHOXY-5-METHYLPYRAZIN-2-YL)-2-(4-'1,3,4-OXADIAZOL-2-YL!PHENYL)PYRIDINE-3 SULPHONAMIDE AS AN ANTICANCER AGENT	

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO REQUIREMENT FOR ELECTION/RESTRICTION

Dear Sir:

In accordance with the Office Action dated March 2, 2009, restriction to one of the following inventions is required:

- Group I Claim(s) 26-28 and 31-43, drawn to a method of treating cancer, reducing abnormal proliferation in a cancerous cell or inducing apoptosis in a cancerous cell, comprising administering an effective amount of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide.
- Group II Claim(s) 29, drawn to a method of providing an anti-angiogenic and vascular targeting agent in blood vessels supplying a cancer cell comprising administering an effective amount of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide.
- Group III Claim(s) 30, drawn to a method of providing an anti-angiogenic effect comprising administering an effective amount of N-(3-methoxy-5-

methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide.

Group IV Claim(s) 44-47, drawn to a method of inhibiting, preventing or treating bone metastases and inhibiting invasion comprising administering an effective amount of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide.

Group V Claim(s) 49, drawn to a method for the prevention or treatment of pain associated with elevated endothelin-I production comprising administering an effective amount of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide.

Group VI Claim(s) 50, drawn to a method for the prevention or treatment of pain associated with stimulation of the ET_A receptor comprising administering an effective amount of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide.

Applicants hereby elect Group I, claims 26-28 and 31-43, drawn to a method of treating cancer, reducing abnormal proliferation in a cancerous cell or inducing apoptosis in a cancerous cell, comprising administering an effective amount of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide.

Applicants also note that the Office Action suggests a requirement for an election of a species of cancer. Applicants hereby elect prostate cancer.

Application No.: 10/524,963
Docket No.: 100815-1P US

The above elections have been made without prejudice to Applicants' right to prosecute any cancelled subject matter in a timely filed continuation/divisional application. Moreover, Applicants believe that the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100815-1P US.

Respectfully submitted,

/Jacob G. Weintraub/

Name: Jacob G. Weintraub
Dated: March 18, 2009
Reg. No.: 56,469
Phone No.: 781 839 4182
Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham, MA 02451